PRECIGEN, INC. Proceeds from Divestiture of Businesses
PRECIGEN, INC. (PGEN) reported Proceeds from Divestiture of Businesses of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2025-03-19
- PRECIGEN, INC. proceeds from divestiture of businesses for the quarter ending 2023-12-31 was $0.00.
- PRECIGEN, INC. proceeds from divestiture of businesses for the quarter ending 2022-12-31 was $0.00.
- PRECIGEN, INC. proceeds from divestiture of businesses for the quarter ending 2021-12-31 was $0.00.
- PRECIGEN, INC. proceeds from divestiture of businesses for the quarter ending 2021-09-30 was $0.00.
- PRECIGEN, INC. proceeds from divestiture of businesses for fiscal 2024 was $0.00.
- PRECIGEN, INC. proceeds from divestiture of businesses for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PRECIGEN, INC. proceeds from divestiture of businesses for fiscal 2022 was $162.31M.
- PRECIGEN, INC. proceeds from divestiture of businesses for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Proceeds from Divestiture of Businesses | Proceeds from Divestiture of Businesses 3 month | Proceeds from Divestiture of Businesses 6 month | Proceeds from Divestiture of Businesses 9 month | Proceeds from Divestiture of Businesses 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-19 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $0.00 10-K · filed 2025-03-19 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $162.31M 10-K · filed 2025-03-19 | |||
| 2022-09-30 | $162.31M 10-Q · filed 2023-11-09 | ||||
| 2022-08-18 | $162.31M 10-K · filed 2025-03-19 | ||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $0.00 derived: sum of 2 quarters · filed 2024-03-19 | $0.00 derived: sum of 3 quarters · filed 2024-03-19 | $0.00 10-K · filed 2024-03-19 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $0.00 derived: sum of 4 quarters · filed 2023-03-06 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-06 | $0.00 derived: sum of 3 quarters · filed 2023-03-06 | $64.24M 10-K · filed 2023-03-06 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $0.00 derived: sum of 2 quarters · filed 2021-11-08 | $64.24M 10-Q · filed 2021-11-08 | $64.24M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $64.24M 10-Q · filed 2021-08-09 | $64.24M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $64.24M 10-Q · filed 2021-05-10 | $64.24M derived: sum of 2 quarters · filed 2022-03-01 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |